PDE5 inhibitors. A new option in the treatment of ureteral colic?;PDE-5-inhibitoren. Ein neuer therapieansatz in der behandlung der harnleiterkolik?

Urologe - Ausgabe A

Volumn 46, Issue 9, 2007, Pages 1219-1223

  Gratzke, C ^a   Uckert S ^b   Reich, O ^a   Schlenker, B ^a   Tilki, D ^a   Seitz, M ^a   Stief, C G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclic GMP; PDE5 inhibitors; Phosphodiesterases (PDE); Ureter; Urinary stone disease

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; KIDNEY COLIC; MUSCLE RELAXATION; MUSCLE TONE; RADIOIMMUNOASSAY; SMOOTH MUSCLE; URETER;

AGED; CARBOLINES; COLIC; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; ISOMETRIC CONTRACTION; MALE; MIDDLE AGED; MUSCLE, SMOOTH; ORGAN CULTURE TECHNIQUES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RADIOIMMUNOASSAY; SULFONES; TRIAZINES; URETER; URETERAL CALCULI; URETERAL DISEASES;

EID: 34648831670     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1409-3     Document Type: Article

References (26)

1. Moe OW (2006) Kidney stones: pathophysiology and medical management. Lancet 367: 333-344
2. Coll DM, Varanelli MJ, Smith RC (2002) Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol 178: 101-103
3. Roberts WW, Cadeddu JA, Micali S et al. (1998) Ureteral stricture formation after removal of impacted calculi. J Urol 159: 723-726
4. Porpiglia F, Destefanis P, Fiori C, Fontana D (2000) Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 56: 579-582
5. Sivrikaya A, Celik OF, Sivrikaya N, Ozgur GK (2003) The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle. Int Urol Nephrol 35: 479-483
6. Ahmad M, Chaughtai MN, Khan FA (1991) Role of prostaglandin synthesis inhibitors in the passage of ureteric calculus. J Pak Med Assoc 41: 268-270
7. Cervenakov I, Fillo J, Mardiak J et al. (2002) Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker Tamsulosin. Int Urol Nephrol 34: 25-29
8. Dellabella M, Milanese G, Muzzonigro G (2003) Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 170: 2202-2205
9. Pozzan T, Rizzuto R, Volpe P, Meldolesi J (1994) Molecular and cellular physiology of intracellular calcium stores. Physiol Rev 74: 595-636
10. Schmidt HH, Lohmann SM, Walter U (1993) The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1178: 153-175
11. Briganti A, Salonia A, Deho' F et al. (2005) Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 23: 374-384
12. Sairam K, Kulinskaya E, McNicholas TA et al. (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90: 836-839
13. McVary T, Roehrborn CG, Kaminetsky JC et al. (2006) The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia. Eur Urol 5(Suppl 2): 196
14. Truss MC, Stief CG, Uckert S et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19: 344-350
15. Berman JR, Berman LA, Lin H et al. (2001) Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J Sex Marital Ther 27: 411-420
16. Taher A, Schulz-Knappe P, Meyer M et al. (1994) Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol 12: 286-291
17. Kühn R, Uckert S, Stief CG et al. (2000) Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urol Res 28: 110-115
18. Saighi D, Zerbib M, Thiounn N et al. (2000) In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a phosphodiesterase inhibitor. Prog Urol 10: 1161-1168
19. Becker AJ, Stief CG, Meyer M et al. (1998) The effect of the specific phosphodiesterase-IV-inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo. J Urol 160: 920-925
20. Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12: 19-27
21. Jeremy JY, Ballard SA, Naylor AM et al. (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958-963
22. Chuang AT, Strauss JD, Murphy RA, Steers WD (1998) Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 160: 257-261
23. Stief CG, Uckert S, Truss MC et al. (1996) A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urol Res 24: 333-337
24. Lau LC, Adaikan PG (2006) Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. Eur J Pharmacol 541: 184-190
25. Nies AT, Spring H, Thon WF et al. (2002) Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J Urol 167: 2271-2275
26. Holdgate A, Carissa MO (2005) Is there a role for antimuscarinics in renal colic? A randomized controlled trial. J Urol 174: 572-575